The Cannabis Extraction Product as an Adjuvant
Treatment in Tourette’s Syndrome: A
Case Report:
Auempa Kanjanarangsichai MD¹, Witoon Mitarnun MD², Nutchaya Laoharattanahirun MD²,
Panomporn Junlaor PharmD³, Pawarin Nonghan BNS⁴
Affiliation : ¹ Department of Social Medicine, Buriram Hospital, Buriram, Thailand ² Department of Medicine, Buriram Hospital, Buriram, Thailand ³ Department of Pharmacy, Buriram Hospital, Buriram, Thailand ⁴ Out Patient Department, Buriram Hospital, Buriram, Thailand
Tourette’s syndrome (TS) is a pediatric onset of neuropsychiatric disorder characterized by motor and vocal tics. First line medication is
dopaminergic blocking agents. Yet, these drugs are not effective in all patients and sometimes the side effects are intolerance. Cannabis and its
derivatives are to use as an adjuvant treatment. They are used to improve tics in TS patients who failed from the first line treatment. The aim of
the present report was to describe the clinical course after using the Government Pharmaceutical Organization (GPO) medical cannabis extraction
product as an adjuvant treatment in TS patient. Here, the researchers reported a case of a 26-year-old female patient who had TS. She had received
sublingual medical cannabis product. The clinical course and disease severity were recorded before and during the administration of the medical
cannabis extraction product using several standards severity score: The Yale Global Tic Severity Scale (YGTSS), Tourette’s Syndrome Severity Scale
(TSSS), Tourette’s Disorder Scale (TODS), and quality of life using a standardized measure of health-related quality of life developed by the Euro
Quality of life group (EQ-5D-5L). The researchers’ observation showed that sublingual administration of medical cannabis extraction product
[tetrahydrocannabinol (THC):cannabidiol (CBD) 1:1 and THC enriched] improved both motor and vocal tics without significant adverse effect
that came out to be improving the patient’s quality of life as a whole.
Received 24 May 2021 | Revised 10 September 2021 | Accepted 10 September 2021
doi.org/10.35755/jmedassocthai.2021.10.13011
Keywords :
Tourette’s Syndrome (TS); The Government Pharmaceutical Organization (GPO); Medical cannabis extraction product; Cannabidiol;
Tetrahydrocannabinol
All Articles
Download